• OPEN AN ACCOUNT
Indian Indices
Nifty
25,019.80 -42.30
(-0.17%)
Sensex
82,330.59 -200.15
( -0.24%)
Bank Nifty
55,354.90 -0.70
( 0.00%)
Nifty IT
37,972.35 -321.45
( -0.84%)
Global Indices
Nasdaq
42,674.05 330.30
(0.78%)
Dow Jones
5,978.97 41.04
(0.69%)
Hang Seng
37,763.30 7.79
(0.02%)
Nikkei 225
8,684.56 50.81
(0.59%)
Forex
USD-INR
85.50 0.17
(0.19%)
EUR-INR
95.69 0.13
(0.13%)
GBP-INR
113.61 0.11
(0.10%)
JPY-INR
0.59 0.00
(0.74%)

EQUITY - MARKET SCREENER

A F Enterprises Ltd Partly Paidup
Industry :  Trading
BSE Code
ISIN Demat
Book Value()
890208
IN9663P01013
2.5
NSE Symbol
P/E(TTM)
Mar.Cap( Cr.)
N.A
0
10.77
EPS(TTM)
Face Value()
Div & Yield %
0
2.5
0
 

raymond ltd
Sun Pharma Advanced Research Company submits IND application to USFDA
Mar 31,2025
Sun Pharma Advanced Research Company announced submission of an Investigational New Drug (IND) application with the US Food and Drug Administration (FDA). The IND application supports the next phase of development of SBO-154 which has completed the required IND-enabling preclinical studies with favorable results. A global phase 1 dose-escalation and expansion study has been planned to evaluate SBO-154 in treatment of solid tumors.

“SBO-154, our first ADC is ready to advance in phase 1 with this IND submission, and this is an important milestone for SPARC as we hope to improve lives of cancer patients globally.” said Anil Raghavan, CEO of SPARC.

SBO-154 is a novel humanized MUC1-SEA-targeted ADC developed by SPARC for the treatment of advanced solid tumors. SBO-154 specifically binds with high affinity to the SEA domain of MUC1, and functions by the release of the antimitotic payload after internalization and cleavage. The released payload inhibits cell division and, thereby contributes to the shrinkage of tumors. SPARC had licensed anti-MUC1 antibody from Biomodifying a startup from the University of Tel Aviv.